ENTA vs. GNFT, ARCT, IRWD, INVA, LQDA, VRNA, GYRE, ARQT, OPK, and BCYC
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Genfit (GNFT), Arcturus Therapeutics (ARCT), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Liquidia (LQDA), Verona Pharma (VRNA), Gyre Therapeutics (GYRE), Arcutis Biotherapeutics (ARQT), OPKO Health (OPK), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
Enanta Pharmaceuticals (NASDAQ:ENTA) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 2 articles in the media. Genfit's average media sentiment score of 0.94 beat Enanta Pharmaceuticals' score of 0.93 indicating that Genfit is being referred to more favorably in the news media.
Genfit has lower revenue, but higher earnings than Enanta Pharmaceuticals.
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 13.6% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Genfit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Genfit has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -180.76%. Genfit's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.
Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Enanta Pharmaceuticals presently has a consensus target price of $19.00, suggesting a potential upside of 52.37%. Genfit has a consensus target price of $11.00, suggesting a potential upside of 112.36%. Given Genfit's stronger consensus rating and higher probable upside, analysts clearly believe Genfit is more favorable than Enanta Pharmaceuticals.
Enanta Pharmaceuticals received 246 more outperform votes than Genfit when rated by MarketBeat users. However, 68.09% of users gave Genfit an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
Summary
Genfit beats Enanta Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
